Altimmune (ALT) announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Jordt succeeds Jose Ochoa, who is leaving Altimmune to pursue other opportunities. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company (LLY)
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALT:
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
- Altimmune Appoints Raymond Jordt as Chief Business Officer
- Altimmune 24-week NAFLD data ‘strong and encouraging,’ says Piper Sandler
- Altimmune announces topline results from 24-week trial of pemvidutide
- Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)